Core Viewpoint - Curanex Pharmaceuticals has successfully completed a dose-range finding toxicology study for its lead botanical drug candidate, Phyto-N, which shows no toxicological significance at maximum feasible doses, allowing progression to GLP toxicology studies for an IND application targeted for Q4 2026 [1][5][6] Group 1: Study Results - The dose-range finding toxicology study involved administering Phyto-N twice daily for 28 days in both rats and dogs, with the highest dose being approximately six times the proposed clinical oral dose in dogs and four times in rats [3] - Comprehensive safety assessments were conducted, including hematology, coagulation parameters, serum biochemistry, and organ examinations, with no treatment-related adverse findings observed [4] Group 2: Historical Context and Development Plans - Phyto-N has over 30 years of established human use in China, administered at a daily dose of 30 g for inflammatory diseases, demonstrating a favorable tolerability profile [2][9] - The company is conducting a full suite of nonclinical studies required by the FDA, including GLP toxicology and pharmacokinetics, to support its IND application [2][10] - Phase 1 clinical development is planned to initiate in Australia in Q4 2026, contingent on the completion of required studies and regulatory clearance [9][10] Group 3: Company Overview - Curanex Pharmaceuticals is a development-stage company focused on botanical drugs for inflammatory diseases, with Phyto-N as its lead candidate targeting moderate-to-severe ulcerative colitis, a condition affecting approximately 5 million patients globally [7][10] - Phyto-N is derived from a single plant species with demonstrated anti-inflammatory properties and has been validated in animal models for multiple inflammatory diseases [8][10]

Core Insights - Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise in immunology and infectious diseases, which aligns with the company's therapeutic focus and clinical development roadmap [1][9] Group 1: New Appointments - Dr. Taku Kambayashi is a Professor at the University of Pennsylvania with expertise in immune cell signal transduction pathways, focusing on therapies for autoimmune and inflammatory diseases [2][3] - Dr. Selvakumar Subbian is a Professor at Rutgers University with over 25 years of experience in microbial pathogenesis, particularly in pulmonary infectious diseases like tuberculosis and COVID-19 [5][6] Group 2: Research Contributions - Dr. Kambayashi's research includes TSLP-stimulated T cells and their implications for obesity-related disorders, as well as therapeutic manipulation of regulatory T cell homeostasis in diseases such as multiple sclerosis and diabetes [3][4] - Dr. Subbian's laboratory has developed rabbit models for studying tuberculosis, contributing to host-directed therapy that enhances antibiotic efficacy [6][8] Group 3: Company Overview - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, showing anti-inflammatory properties and a history of human use in China [10][11] - Phyto-N has been validated in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis, and is preparing for an Investigational New Drug (IND) submission [11]

Core Insights - Curanex Pharmaceuticals Inc. has established a new Scientific Advisory Board to support its executive team and Board of Directors, focusing on the development of botanical drugs for inflammatory diseases [1][2] Group 1: Scientific Advisory Board - The Scientific Advisory Board will assist in research and development, including clinical trials and intellectual property enhancement, while also shaping the commercialization strategy [2] - The initial board will consist of five members, including two industry experts and three leading academic figures [3] Group 2: Company Overview - Curanex is a development-stage pharmaceutical company based in Jericho, New York, dedicated to botanical drugs for inflammatory diseases, with its lead candidate being Phyto-N [5] - Phyto-N is a botanical extract with proven anti-inflammatory properties, having a history of use in treating thousands of patients over 30 years in China [5] Group 3: Development Focus - The company has validated Phyto-N's effects in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis [6] - Phyto-N is currently undergoing FDA-required preclinical studies, with Phase I clinical trials expected to start in Q4 2026, pending regulatory clearance [7]

Core Viewpoint - Curanex Pharmaceuticals Inc. has successfully completed its initial public offering (IPO), raising a total of $17.25 million through the sale of 4,312,500 shares, with an additional 562,500 shares sold under the over-allotment option at $4.00 per share [1][2]. Group 1: IPO Details - Dominari Securities LLC acted as the lead underwriter for the IPO, with Pacific Century Securities LLC and Revere Securities LLC serving as co-underwriters [3]. - The IPO was registered with the SEC under Form S-1 and was declared effective on August 12, 2025 [4]. Group 2: Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focusing on botanical drugs for inflammatory diseases [6]. - The company's lead candidate, Phyto-N, is a botanical extract with anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [7].

Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focused on discovering and developing botanical drugs for inflammatory diseases [5] - The company's lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [5][6] Initial Public Offering (IPO) Details - Curanex announced the closing of its IPO, offering 3,750,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of $15 million [1] - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025 [1] - Underwriters were granted an option to purchase up to 562,500 additional shares within 45 days from the closing of the Offering [1] Underwriters and Legal Counsel - Dominari Securities LLC served as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [2] - The Crone Law Group, P.C. acted as counsel to the company, while Sichenzia Ross Ference Carmel LLP served as lead counsel to the underwriters [2] Regulatory Filings - A registration statement on Form S-1 was filed with the SEC and declared effective on August 12, 2025, with the Offering made only by means of a prospectus [3]

Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]